(编辑：杨燕 林辰) （港交所披露易） 近日，景泽生物医药(合肥)股份有限公司向港交所递交上市申请，作为一家专注于辅助生殖药物、眼科 药物两大赛道的生物制药公司，景泽生物建立了全面的研发体系、以及商业级规模的内部生产能力，自 主研发了多条产品管线、并且已将两个领域多款高技术且极具商业前景的候选药物推进至临床试验后期 及商业化阶段。 ...

| | 27/06/2025 整體協調人公告 - 委任 | | --- | --- | | 27/06/2025 | 景澤生物醫藥（合肥）股份有限公司 - B 27/06/2025 申請版本（第一次呈交） 全文檔案 [四] 多檔案 > | 据此前招股书披露，景泽生物是一家专注于辅助生殖药物和眼科药物两大高成长赛道的生物制药公司。以未被满足的临床需求为导向，该公司建立了全面的 研发体系以及商业级规模的生产能力。凭借体系能力，自主研发了多条产品管线，并且已将多款高技术壁垒且极具商业前景的药物推进至临床后期及商业化 阶段。 景泽生物医药(合肥)股份有限公司(简称：景泽生物)于6月27日递交的港股招股书满6个月，于12月27日失效，递表时中金公司、国元国际为其联席保荐人。 ...

据此前招股书披露，景泽生物是一家专注于辅助生殖药物和眼科药物两大高成长赛道的生物制药公司。以未被满足的临床需求为导向，该公司建立了全面的 研发体系以及商业级规模的生产能力。凭借体系能力，自主研发了多条产品管线，并且已将多款高技术壁垒且极具商业前景的药物推进至临床后期及商业化 阶段。 智通财经APP获悉，景泽生物医药(合肥)股份有限公司(简称：景泽生物)于6月27日递交的港股招股书满6个月，于12月27日失效，递表时中金公司、国元国 际为其联席保荐人。 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Jingze Biotech regarding its recent shareholder changes and other compliance matters as part of its application for listing on the Hong Kong Stock Exchange [1][2]. Group 1: Regulatory Requirements - CSRC requires Jingze Biotech to explain the reasons for new shareholders joining in the last 12 months and the rationale behind the share prices, including any discrepancies and potential issues of abnormal pricing or benefit transfer [1]. - The company must clarify the progress of state-owned shareholders in handling state-owned stock identification [1]. - Jingze Biotech is asked to confirm whether its business scope, particularly in "cell technology research and application" and "developing candidate drugs that regulate pathogenic genes at the DNA or RNA level," involves any foreign investment restrictions or prohibited areas [1]. - The company needs to provide details on its previous A-share listing guidance and whether it plans to continue pursuing A-share listing, including any significant impacts on the current listing process [1]. Group 2: Company Overview - Jingze Biotech is a biopharmaceutical company focused on high-growth sectors of assisted reproductive drugs and ophthalmic drugs, addressing unmet clinical needs [2]. - The company has established a comprehensive R&D system and commercial-scale production capabilities, having developed multiple product pipelines with high technical barriers and significant commercial potential, advancing several drugs to late-stage clinical and commercialization phases [2].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Jingze Biotech regarding its recent shareholder changes and compliance with foreign investment policies as part of its listing application process [1][2]. Group 1: Regulatory Requirements - CSRC requires Jingze Biotech to explain the reasons for new shareholders joining in the last 12 months and the rationale behind the share prices, including any discrepancies and potential issues of abnormal pricing or benefit transfer [1] - The company must clarify the progress of state-owned shareholders in handling state-owned stock identification [1] - Jingze Biotech is asked to confirm whether its business scope, particularly in "cell technology research and application" and "developing candidate drugs that regulate pathogenic genes at the DNA or RNA level," involves any areas restricted or prohibited for foreign investment [1] Group 2: Company Overview - Jingze Biotech focuses on high-growth sectors of assisted reproductive drugs and ophthalmic drugs, addressing unmet clinical needs with a comprehensive R&D system and commercial-scale production capabilities [2] - The company has developed multiple product pipelines and advanced several high-tech, commercially promising drugs to late-stage clinical and commercialization phases [2]

Group 1 - The company, Renhe Pharmaceutical, stated that it has not reached an agreement with Weimou Biotech for the production of innovative drugs by Jiangxi Shining Weimou Pharmaceutical Co., Ltd [1] - There is currently no collaboration between Weimou Biotech and Renhe Pharmaceutical regarding ophthalmic drugs [1]

Core Viewpoint - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. plans to raise up to 850 million yuan through a private placement to enhance R&D innovation and strengthen its market position in the ophthalmic drug sector [1][5] Group 1: Financial Performance - Since its listing in December 2016, the company's revenue has grown from 339 million yuan in 2016 to 1.943 billion yuan in 2024, representing a nearly sixfold increase with a compound annual growth rate (CAGR) of 24.39% [2] - Net profit increased from 54.28 million yuan in 2016 to 338 million yuan in 2024, also showing over sixfold growth and a CAGR of 25.69% [2] - In Q1 of the current year, the company achieved a revenue of 536 million yuan, a year-on-year increase of 53.24%, and a net profit of 146 million yuan, which is more than three times the previous year [2] Group 2: R&D Investment and Strategy - The company maintains a high R&D intensity, with R&D expenditure reaching 235 million yuan in 2024, accounting for 12.11% of its revenue [4] - The planned R&D center aims to create a benchmark in the ophthalmic field, integrating smart laboratory systems, international R&D collaboration, and innovation platforms [4][5] - The implementation of the fundraising project is expected to enhance the company's R&D capabilities, broaden its product pipeline, and optimize existing product structures, ultimately driving sustainable growth [5] Group 3: Competitive Advantage - The company has established a strong competitive advantage in the ophthalmic drug sector due to its focus on R&D and continuous high investment in innovation [3] - The diverse product line covers various common eye diseases, contributing to the company's robust market position [3]